MarketWatch.com - MarketPulse
NEW YORK (MarketWatch) -- IDM Pharma Inc. said Monday that Sanofi-Aventis has decided to stop participating in the development of investigational melanoma therapy Uvidem. As a result, IDM Pharma, an Irvine, Calif.-based biotechnology company, said it expects to restructure, cut its workforce and review the assets and costs associated with products under development. The board is expected to approve the final restructuring plan during the first quarter of 2008. Shares of IDM Pharma closed Friday at 94 cents.